← FDA DRUG APPROVALS

FDA ANDA · ANDA078651

ROCURONIUM

rocuronium bromide

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA078651
TYPE
ANDA
ORIGINAL APPROVAL
2008-12-29
LATEST ACTION
2020-08-07
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ROCURONIUM BROMIDEPrescription
ROCURONIUM BROMIDE 100MG/10ML (10MG/ML) · INJECTABLE · INJECTION
ROCURONIUM BROMIDEPrescription
ROCURONIUM BROMIDE 50MG/5ML (10MG/ML) · INJECTABLE · INJECTION

Approval history

2020-08-07Labeling · Supplement 8 · standardAP
2020-08-07Labeling · Supplement 7 · standardAP
2018-07-26Labeling · Supplement 6 · standardAP
2015-07-02Labeling · Supplement 4 · standardAP
2015-07-02Labeling · Supplement 5 · standardAP
2011-05-24Labeling · Supplement 2AP
2008-12-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →